For a full breakdown of the regulatory landscape, see BPC-157 and the FDA's Category 2 classification
Additional animal injury models highlight the anti-inflammatory and pain reduction properties of BPC-157 [12, 13]
Severe Anemia Risks: In people with severe megaloblastic anemia, aggressive treatment can cause low potassium (hypokalemia) and sudden, serious complications
Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research
Individuals with polycythemia or blood disorders These patients already have increased red cells and dont need the boost
However, some individuals may experience local irritation at the injection site, mild gastrointestinal disturbances, or, rarely, allergic reactions